Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71610-218

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-218). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 30 mg (71610 0218 30)

Label for Duloxetine Delayed-Release (DR) capsules, each containing 30 mg of Duloxetine Hydrochloride. The label specifies 30 capsules per package, indicates storage instructions, and lists Aphena Pharma Solutions - Tennessee, LLC as the labeler located in Cookeville, TN. It includes manufacturing details and standard drug handling warnings.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride, the active ingredient in Duloxetine Delayed-Release capsules, shown as a molecular diagram depicting its atomic bonds and arrangement.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time in days from randomization for Duloxetine versus placebo treatments. The x-axis represents time in days up to 250, and the y-axis represents the proportion of patients with relapse ranging from 0.0 to 1.0. The graph shows two curves labeled for placebo and Duloxetine treatments, illustrating relapse trends over time.*

FDA Label Image

Figure 2 (Duloxetine 03)

A line graph showing the proportion of patients with relapse over time from randomization (in days) comparing Duloxetine and placebo treatments. The x-axis represents days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. Duloxetine treatment is represented by a solid line, and placebo by a dashed line, illustrating lower relapse proportions for Duloxetine over time.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. Four lines represent groups treated with Duloxetine at 60 mg BID, 60 mg QD, 20 mg QD, and placebo. The graph shows decreasing patient improvement percentages as pain improvement increases, comparing different Duloxetine doses and placebo efficacy.*

FDA Label Image

Figure 4 (Duloxetine 05)

Line graph depicting the percentage of patients improved against percent improvement in pain from baseline, comparing Duloxetine 60mg twice daily (BID), Duloxetine 60mg once daily (QD), and placebo groups. The horizontal axis shows percent improvement in pain, and the vertical axis indicates the percentage of patients improved. Data points for Duloxetine BID and QD groups are consistently higher than placebo across pain improvement levels.*

FDA Label Image

Figure 7 (Duloxetine 06)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines plot the data: one for placebo (marked with crosses) and one for Duloxetine (marked with diamonds), indicating higher percentages of patient improvement with Duloxetine across pain improvement thresholds.*

FDA Label Image

Figure 8 (Duloxetine 07)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between Placebo and Duloxetine (DUL) 60 mg once daily. The graph shows two curves, with Duloxetine consistently demonstrating higher patient improvement rates across increasing pain improvement percentages.*

FDA Label Image

Figure 9 (Duloxetine 08)

A line graph showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. Two lines compare outcomes: one for placebo and one for DUL 60/120 mg once daily, indicating higher patient improvement percentages with DUL across pain improvement levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.